{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,31]],"date-time":"2026-07-31T05:31:18Z","timestamp":1785475878771,"version":"3.56.0"},"reference-count":38,"publisher":"Oxford University Press (OUP)","issue":"12","license":[{"start":{"date-parts":[[2025,12,3]],"date-time":"2025-12-03T00:00:00Z","timestamp":1764720000000},"content-version":"vor","delay-in-days":2,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["UM1CA186689"],"award-info":[{"award-number":["UM1CA186689"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["P30CA068485"],"award-info":[{"award-number":["P30CA068485"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["HHSN261200800001E"],"award-info":[{"award-number":["HHSN261200800001E"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,12,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Mutations in TP53 are common in gastroesophageal cancer and portend a poor prognosis. Tumor cells with TP53 mutations increasingly rely on ataxia-telangiectasia and Rad3-related (ATR) protein to respond to and repair DNA damage induced by cytotoxic chemotherapy. We aimed to assess the efficacy of ATR inhibitor, berzosertib, with irinotecan in patients harboring TP53-mutated, metastatic gastroesophageal cancer.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>NCI 10211 is a phase II trial that enrolled patients with TP53-mutated, unresectable or metastatic gastroesophageal adenocarcinoma to receive berzosertib with irinotecan on day 1, 15 in 28-day cycles. Initially, patients who had progressed on at least 1 prior line of therapy were enrolled which was later amended to at least 2 prior lines of therapy. The primary outcome was objective response rate (ORR), and secondary outcomes included progression-free survival (PFS) and overall survival (OS). Nine patients underwent biopsy for correlative studies, which included assay evaluation of \u03b3H2AX, NBS1, and KAP1 p-Ser 824 expression.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Of the 17 patients enrolled, 16 were evaluable for the primary endpoint of ORR. The ORR was 0%, disease control rate (DCR) of 56.2%, median PFS (mPFS) of 4.01 months, and median OS (mOS) of 6.21 months. The study did not meet its primary endpoint. The most common treatment-related adverse events were nausea (52.9%), anemia (41.2%), diarrhea (41.2%), and lymphopenia (41.2%) without any unexpected adverse events.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>This novel combination of ATR inhibitor berzosertib with irinotecan did not lead to objective responses in patients with TP53-mutated, advanced gastroesophageal adenocarcinoma. The combination regimen was well tolerated without unexpected adverse events. This trial was registered with ClinicalTrials.gov (NCT03641313).<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/oncolo\/oyaf400","type":"journal-article","created":{"date-parts":[[2025,12,2]],"date-time":"2025-12-02T12:58:50Z","timestamp":1764680330000},"source":"Crossref","is-referenced-by-count":1,"title":["NCI 10211: a phase II, single-arm study of berzosertib in combination with irinotecan in patients with advanced\n                    <i>TP53<\/i>\n                    mutant gastroesophageal cancer"],"prefix":"10.1093","volume":"30","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4494-1350","authenticated-orcid":false,"given":"Margaret C","family":"Wheless","sequence":"first","affiliation":[{"name":"Vanderbilt University Medical Center\/Vanderbilt-Ingram Cancer Center , Nashville, TN 37232,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shannon","family":"Stockton","sequence":"additional","affiliation":[{"name":"Florida Cancer Specialists and Research Institute , Largo, FL 33770,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Heloisa P","family":"Soares","sequence":"additional","affiliation":[{"name":"University of Utah Huntsman Cancer Institute Division of Oncology, , Salt Lake City, UT 84112,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4970-5189","authenticated-orcid":false,"given":"Farshid","family":"Dayyani","sequence":"additional","affiliation":[{"name":"University of California Irvine Chao Family Comprehensive Cancer Center , Orange, CA 92868,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anwaar","family":"Saeed","sequence":"additional","affiliation":[{"name":"University of Pittsburgh Medical Center\/Hillman Cancer Center Department of Medicine, , Pittsburgh, PA 15261,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Edward","family":"Kim","sequence":"additional","affiliation":[{"name":"UC Davis Comprehensive Cancer Center , Sacramento, CA 95817,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ning","family":"Jin","sequence":"additional","affiliation":[{"name":"Ohio State University Comprehensive Cancer Center Department of Medicine, , Columbus, OH 43210,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"George","family":"Yacoub","sequence":"additional","affiliation":[{"name":"Atrium Health Wake Forest Baptist , Winston-Salem, NC 27157,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vaia","family":"Florou","sequence":"additional","affiliation":[{"name":"University of Utah Huntsman Cancer Institute Division of Oncology, , Salt Lake City, UT 84112,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gregory D","family":"Ayers","sequence":"additional","affiliation":[{"name":"Vanderbilt University Medical Center\/Vanderbilt-Ingram Cancer Center , Nashville, TN 37232,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bella S","family":"Guerrouahen","sequence":"additional","affiliation":[{"name":"The University of Texas MD Anderson Cancer Center , Houston, TX 77030,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alejandro","family":"Contreras","sequence":"additional","affiliation":[{"name":"The University of Texas MD Anderson Cancer Center , Houston, TX 77030,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Li","family":"Li","sequence":"additional","affiliation":[{"name":"Frederick National Laboratory for Cancer Research , Frederick, MD 21701,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katherine V","family":"Ferry-Galow","sequence":"additional","affiliation":[{"name":"Frederick National Laboratory for Cancer Research , Frederick, MD 21701,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Steven","family":"Gore","sequence":"additional","affiliation":[{"name":"National Cancer Institute , Bethesda, MD 20892,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Satya","family":"Das","sequence":"additional","affiliation":[{"name":"Phanes Therapeutics , San Diego, CA 92121,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7571-2385","authenticated-orcid":false,"given":"Jordan","family":"Berlin","sequence":"additional","affiliation":[{"name":"Vanderbilt University Medical Center\/Vanderbilt-Ingram Cancer Center , Nashville, TN 37232,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2025,12,3]]},"reference":[{"key":"2025122018415669700_oyaf400-B1","author":"National Cancer Institute Surveillance Epidemiology, and End Results Program"},{"key":"2025122018415669700_oyaf400-B2","author":"National Cancer Institute Surveillance Epidemiology, and End Results Program"},{"key":"2025122018415669700_oyaf400-B3","doi-asserted-by":"publisher","first-page":"1469","DOI":"10.1007\/s11912-024-01607-5","article-title":"Evolving treatment landscape for advanced esophageal and gastroesophageal junction adenocarcinoma","volume":"26","author":"Wheless","year":"2024","journal-title":"Curr Oncol Rep"},{"key":"2025122018415669700_oyaf400-B4","doi-asserted-by":"publisher","first-page":"1181","DOI":"10.1016\/s1470-2045(23)00515-6","article-title":"Pembrolizumab plus chemotherapy versus placebo plus chemotherapy for HER2-negative advanced gastric cancer (KEYNOTE-859): a multicentre, randomised, double-blind, phase 3 trial","volume":"24","author":"Rha","year":"2023","journal-title":"Lancet Oncol"},{"key":"2025122018415669700_oyaf400-B5","doi-asserted-by":"publisher","first-page":"759","DOI":"10.1016\/s0140-6736(21)01234-4","article-title":"Pembrolizumab plus chemotherapy versus chemotherapy alone for first-line treatment of advanced oesophageal cancer (KEYNOTE-590): a randomised, placebo-controlled, phase 3 study","volume":"398","author":"Sun","year":"2021","journal-title":"Lancet"},{"key":"2025122018415669700_oyaf400-B6","doi-asserted-by":"publisher","first-page":"510","DOI":"10.1038\/s41416-021-01405-x","article-title":"Phase 1 study of the ATR inhibitor berzosertib (formerly M6620, VX-970) combined with gemcitabine \u00b1 cisplatin in patients with advanced solid tumours","volume":"125","author":"Middleton","year":"2021","journal-title":"Br J Cancer."},{"key":"2025122018415669700_oyaf400-B7","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1016\/j.ctrv.2006.09.006","article-title":"Molecular mechanisms of resistance and toxicity associated with platinating agents","volume":"33","author":"Rabik","year":"2007","journal-title":"Cancer Treat Rev"},{"key":"2025122018415669700_oyaf400-B8","doi-asserted-by":"publisher","first-page":"1769","DOI":"10.3390\/cancers6031769","article-title":"Drug resistance in cancer: an overview","volume":"6","author":"Housman","year":"2014","journal-title":"Cancers (Basel)"},{"key":"2025122018415669700_oyaf400-B9","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1159\/000086183","article-title":"Mechanisms of drug resistance in cancer chemotherapy","volume":"14 Suppl 1","author":"Luqmani","year":"2005","journal-title":"Med Princ Pract"},{"key":"2025122018415669700_oyaf400-B10","doi-asserted-by":"publisher","first-page":"1758835918786658","DOI":"10.1177\/1758835918786658","article-title":"Dancing with the DNA damage response: next-generation anti-cancer therapeutic strategies","volume":"10","author":"Minchom","year":"2018","journal-title":"Ther Adv Med Oncol"},{"key":"2025122018415669700_oyaf400-B11","doi-asserted-by":"publisher","first-page":"1658","DOI":"10.1038\/s12276-022-00863-4","article-title":"DNA damage response revisited: the p53 family and its regulators provide endless cancer therapy opportunities","volume":"54","author":"Abuetabh","year":"2022","journal-title":"Exp Mol Med"},{"key":"2025122018415669700_oyaf400-B12","doi-asserted-by":"publisher","first-page":"4780","DOI":"10.1158\/1078-0432.CCR-15-0479","article-title":"Molecular pathways: targeting ATR in cancer therapy","volume":"21","author":"Karnitz","year":"2015","journal-title":"Clin Cancer Res"},{"key":"2025122018415669700_oyaf400-B13","doi-asserted-by":"publisher","first-page":"154","DOI":"10.1016\/j.yexcr.2014.09.002","article-title":"ATM: expanding roles as a chief guardian of genome stability","volume":"329","author":"Shiloh","year":"2014","journal-title":"Exp Cell Res"},{"key":"2025122018415669700_oyaf400-B14","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1097\/00000658-200002000-00005","article-title":"Clinical significance of p53 mutations in adenocarcinoma of the esophagus and cardia","volume":"231","author":"Ireland","year":"2000","journal-title":"Ann Surg"},{"key":"2025122018415669700_oyaf400-B15","first-page":"305","article-title":"Gamma-H2AX\u2014a novel biomarker for DNA double-strand breaks","volume":"22","author":"Kuo","year":"2008","journal-title":"In Vivo"},{"key":"2025122018415669700_oyaf400-B16","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1016\/j.canlet.2011.12.025","article-title":"Use of the \u03b3-H2AX assay to monitor DNA damage and repair in translational cancer research","volume":"327","author":"Ivashkevich","year":"2012","journal-title":"Cancer Lett"},{"key":"2025122018415669700_oyaf400-B17","doi-asserted-by":"publisher","first-page":"401","DOI":"10.1158\/1541-7786.Mcr-11-0134","article-title":"The ATM substrate KAP1 controls DNA repair in heterochromatin: regulation by HP1 proteins and serine 473\/824 phosphorylation","volume":"10","author":"White","year":"2012","journal-title":"Mol Cancer Res"},{"key":"2025122018415669700_oyaf400-B18","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1038\/sj.cr.7310007","article-title":"The role of NBS1 in DNA double strand break repair, telomere stability, and cell cycle checkpoint control","volume":"16","author":"Zhang","year":"2006","journal-title":"Cell Res"},{"key":"2025122018415669700_oyaf400-B19","doi-asserted-by":"publisher","first-page":"3195","DOI":"10.1200\/jco.19.02404","article-title":"Phase I trial of first-in-class ATR inhibitor M6620 (VX-970) as monotherapy or in combination with carboplatin in patients with advanced solid tumors","volume":"38","author":"Yap","year":"2020","journal-title":"J Clin Oncol"},{"key":"2025122018415669700_oyaf400-B20","doi-asserted-by":"publisher","first-page":"1594","DOI":"10.1200\/jco.2017.76.6915","article-title":"Phase I study of ATR inhibitor M6620 in combination with topotecan in patients with advanced solid tumors","volume":"36","author":"Thomas","year":"2018","journal-title":"J Clin Oncol"},{"key":"2025122018415669700_oyaf400-B21","doi-asserted-by":"publisher","first-page":"566","DOI":"10.1016\/j.ccell.2021.02.014","article-title":"Therapeutic targeting of ATR yields durable regressions in small cell lung cancers with high replication stress","volume":"39","author":"Thomas","year":"2021","journal-title":"Cancer Cell"},{"key":"2025122018415669700_oyaf400-B22","doi-asserted-by":"publisher","first-page":"3012","DOI":"10.1200\/JCO.2022.40.16_suppl.3012","article-title":"NCI 9938: phase I clinical trial of ATR inhibitor berzosertib (M6620, VX-970) in combination with irinotecan in patients with advanced solid tumors","volume":"40","author":"Villaruz","year":"2022","journal-title":"Journal of Clinical Oncology"},{"key":"2025122018415669700_oyaf400-B23","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1038\/sj.onc.1202298","article-title":"Evolutionary conservation and somatic mutation hotspot maps of p53: correlation with p53 protein structural and functional features","volume":"18","author":"Walker","year":"1999","journal-title":"Oncogene."},{"key":"2025122018415669700_oyaf400-B24","doi-asserted-by":"publisher","first-page":"464","DOI":"10.1007\/s10120-017-0759-9","article-title":"Irinotecan monotherapy as third-line or later treatment in advanced gastric cancer","volume":"21","author":"Makiyama","year":"2018","journal-title":"Gastric Cancer"},{"key":"2025122018415669700_oyaf400-B25","doi-asserted-by":"publisher","first-page":"3084","DOI":"10.1158\/1078-0432.Ccr-18-2523","article-title":"Evaluation of pharmacodynamic responses to cancer therapeutic agents using DNA damage markers","volume":"25","author":"Wilsker","year":"2019","journal-title":"Clin Cancer Res"},{"key":"2025122018415669700_oyaf400-B26","doi-asserted-by":"publisher","first-page":"5447","DOI":"10.1158\/1078-0432.Ccr-09-3076","article-title":"Development of a validated immunofluorescence assay for \u03b3H2AX as a pharmacodynamic marker of topoisomerase I inhibitor activity","volume":"16","author":"Kinders","year":"2010","journal-title":"Clin Cancer Res"},{"key":"2025122018415669700_oyaf400-B27","doi-asserted-by":"publisher","first-page":"399","DOI":"10.1136\/gutjnl-2015-310888","article-title":"The prognostic value of TP53 mutations in oesophageal \u00adadenocarcinoma: a systematic review and meta-analysis","volume":"66","author":"Fisher","year":"2017","journal-title":"Gut"},{"key":"2025122018415669700_oyaf400-B28","doi-asserted-by":"publisher","first-page":"1224","DOI":"10.1016\/s1470-2045(14)70420-6","article-title":"Ramucirumab plus paclitaxel versus placebo plus paclitaxel in patients with previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (RAINBOW): a double-blind, randomised phase 3 trial","volume":"15","author":"Wilke","year":"2014","journal-title":"Lancet Oncol"},{"key":"2025122018415669700_oyaf400-B29","doi-asserted-by":"publisher","first-page":"481","DOI":"10.1007\/s00280-012-2027-3","article-title":"A randomized phase II study of biweekly irinotecan monotherapy or a combination of irinotecan plus 5-fluorouracil\/leucovorin (mFOLFIRI) in patients with metastatic gastric adenocarcinoma refractory to or progressive after first-line chemotherapy","volume":"71","author":"Sym","year":"2013","journal-title":"Cancer Chemother Pharmacol"},{"key":"2025122018415669700_oyaf400-B30","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1093\/annonc\/mdh007","article-title":"Phase II study of irinotecan and 5-fluorouracil\/leucovorin in patients with primary refractory or relapsed advanced oesophageal and gastric carcinoma","volume":"15","author":"Assersohn","year":"2004","journal-title":"Ann Oncol"},{"key":"2025122018415669700_oyaf400-B31","doi-asserted-by":"publisher","first-page":"1437","DOI":"10.1016\/s1470-2045(18)30739-3","article-title":"Trifluridine\/tipiracil versus placebo in patients with heavily pretreated metastatic gastric cancer (TAGS): a randomised, double-blind, placebo-controlled, phase 3 trial","volume":"19","author":"Shitara","year":"2018","journal-title":"Lancet Oncol"},{"key":"2025122018415669700_oyaf400-B32","doi-asserted-by":"publisher","first-page":"2850","DOI":"10.1093\/annonc\/mdt351","article-title":"Second-line chemotherapy versus supportive cancer treatment in advanced gastric cancer: a meta-analysis","volume":"24","author":"Kim","year":"2013","journal-title":"Ann Oncol"},{"key":"2025122018415669700_oyaf400-B33","doi-asserted-by":"publisher","DOI":"10.1172\/JCI175369","article-title":"Durable responses to ATR inhibition with ceralasertib in tumors with genomic defects and high inflammation","volume":"134","author":"Dillon","year":"2024","journal-title":"J Clin Invest"},{"key":"2025122018415669700_oyaf400-B34","author":"Timothy","year":"2022"},{"key":"2025122018415669700_oyaf400-B35","doi-asserted-by":"publisher","first-page":"CT267","DOI":"10.1158\/1538-7445.Am2025-ct267","article-title":"Abstract CT267: first results of ART0380 (an ATR kinase inhibitor) with low dose \u00adirinotecan in advanced or metastatic solid tumors","volume":"85","author":"Ulahannan","year":"2025","journal-title":"Cancer Res"},{"key":"2025122018415669700_oyaf400-B36","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2022-005041","article-title":"Phase II study of ceralasertib (AZD6738) in combination with durvalumab in patients with advanced gastric cancer","volume":"10","author":"Kwon","year":"2022","journal-title":"J Immunother Cancer"},{"key":"2025122018415669700_oyaf400-B37","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1038\/35094077","article-title":"Rescuing the function of mutant p53","volume":"1","author":"Bullock","year":"2001","journal-title":"Nat Rev Cancer"},{"key":"2025122018415669700_oyaf400-B38","doi-asserted-by":"publisher","first-page":"466","DOI":"10.1177\/1947601911408889","article-title":"Mutations in the p53 tumor suppressor gene: important milestones at the various steps of \u00adtumorigenesis","volume":"2","author":"Rivlin","year":"2011","journal-title":"Genes Cancer"}],"container-title":["The Oncologist"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/oncolo\/advance-article-pdf\/doi\/10.1093\/oncolo\/oyaf400\/65728435\/oyaf400.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/oncolo\/article-pdf\/30\/12\/oyaf400\/65728435\/oyaf400.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/oncolo\/article-pdf\/30\/12\/oyaf400\/65728435\/oyaf400.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,20]],"date-time":"2025-12-20T23:42:05Z","timestamp":1766274125000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/oncolo\/article\/doi\/10.1093\/oncolo\/oyaf400\/8363891"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12,1]]},"references-count":38,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2025,12,1]]}},"URL":"https:\/\/doi.org\/10.1093\/oncolo\/oyaf400","relation":{},"ISSN":["1083-7159","1549-490X"],"issn-type":[{"value":"1083-7159","type":"print"},{"value":"1549-490X","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2025,12]]},"published":{"date-parts":[[2025,12,1]]},"article-number":"oyaf400"}}